The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

Part of paid clinical trials in Plano, Texas.

Sponsor
Texas Retina Associates
Study ID
NCT05486468
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Uveitis
  • Uveitis, Anterior
  • Uveitis, Intermediate
  • Uveitis, Posterior

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Yutiq 0.18 MG Drug Implant — DRUG
    YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
  • Sham Injection — OTHER
    Sham injection

Study Details

The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)

Key Dates

Start date
Oct 5, 2022
Status verified
Aug 2025
Primary completion
Jul 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Arm
    This group will receive two YUTIQ implants at day 1.
  • Sham Comparator: Control Arm
    This group will receive two sham injections at day 1.

Primary Outcome Measure

Recurrence rate of uveitis will be assessed at the 6-month visit [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Texas Retina AssociatesPlanoTexas75075
Jodi Creighton, COA
[email protected]
214-692-6941
Ann Mungioli
[email protected]
214-692-6941
Robert Wang, MD (SUB_INVESTIGATOR)
Rene Choi, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Plano, TX

By research site
Texas Retina Associates· Plano, TX

Related Studies